Clinical Trial Update: A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating oteseconazole (VT-1161) for recurrent vulvovaginal candidiasis has completed, with results posted in December 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvovaginal Candidiasis

Drugs mentioned

• Oteseconazole (oteseconazole)

Snippet

Sponsor: Mycovia Pharmaceuticals Inc. | Conditions: Recurrent Vulvovaginal Candidiasis | Phase 3 | Status: COMPLETED | Results posted: 2021-12-20